

DIAGNOSTICS AND THERAPEUTICS FOR HIV: GLOBAL MARKETS



PHM058B
April 2014

Kritika Chaudhari
Project Analyst

ISBN: 1-56965-767-X

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	3
STUDY GOALS AND OBJECTIVES	3
REASONS FOR DOING THE STUDY	3
INTENDED AUDIENCE	3
SCOPE AND FORMAT	3
METHODOLOGY	4
ANALYST'S CREDENTIALS	4
INFORMATION SOURCES	4
MARKET ANALYSES AND FORECASTS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH ONLINE SERVICES	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
THE SKEWED MARKET	7
HIV THERAPEUTICS MARKET WILL BE WORTH \$19.6 BILLION IN 2018	7
FIXED-DOSE COMBINATION DRUGS AND INTEGRASE INHIBITOR DRUGS WILL DRIVE THE MARKET	7
2013 WHO GUIDELINES WILL EXPAND THE GLOBAL HIV MARKET	8
STRICT ADHERENCE TO ARV TREATMENT REMAINS A CHALLENGE	8
DEMAND FOR ACCESS TO AFFORDABLE MEDICINE	8
SEVEN OF THE EIGHT LEADING ARV DRUGS ARE ON PATENT CLIFF	9
GILEAD SCIENCES WILL CONTINUE TO DOMINATE THE HIV THERAPEUTICS MARKET	9
POC DEVICES FOR CD4 AND VIRAL LOAD TESTING WILL DRIVE THE HIV DIAGNOSTICS MARKET	9
THE U.S. WILL REMAIN THE LEADING NATIONAL MARKET FOR HIV	10
EARLY PROPHYLAXIS IS THE KEY TO HIV MANAGEMENT	10
HIV VACCINES-A LONG ROAD AHEAD	11
TOWARDS AN AIDS-FREE GENERATION	11
<i>SUMMARY TABLE GLOBAL HIV MARKET, THROUGH 2018 (\$ BILLIONS)</i>	12
<i>SUMMARY FIGURE GLOBAL HIV MARKET, 2012-2018 (\$ BILLIONS)</i>	12
CHAPTER 3 OVERVIEW	14
GLOBAL BURDEN OF HIV	14
<i>TABLE 1 TOP 10 LEADING CAUSES OF DEATHS IN THE WORLD, 2011 (MILLIONS)</i>	14
<i>TABLE 2 BURDEN OF HIV BY GEOGRAPHICAL REGIONS</i>	15
GLOBAL RESPONSE TO HIV EPIDEMIC	16
MILESTONES IN HIV RESEARCH	16
<i>TABLE 3 MILESTONES IN THE HISTORY OF HIV</i>	16
TARGETING HIV LIFECYCLE	17
<i>TABLE 4 LIFE CYCLE OF HIV-THERAPEUTICS TARGET POINTS</i>	18
DIAGNOSTIC TOOLS FOR DETECTING HIV INFECTION	19
EFFORTS FOR HIV PROPHYLAXIS	19
FUTURE OF GLOBAL HIV MARKET	20
CONCLUSION	21

TOPIC	PAGE NO.
CHAPTER 4 GLOBAL MARKET	23
GLOBAL HIV MARKET 2012	23
GLOBAL HIV MARKET FORECAST TO 2018	23
TABLE 5 FORECASTED NUMBER OF PEOPLE RECEIVING ARV THERAPY, 2012-2018 (MILLIONS)	23
HIV MARKET BY GEOGRAPHICAL REGIONS	24
TABLE 6 ARV DRUGS SALES REVENUE BY GEOGRAPHIC REGIONS, THROUGH 2018 (\$ BILLIONS)	24
TABLE 7 ARV DRUGS MARKET SHARE BY GEOGRAPHIC REGIONS, 2012-2018 (%)	24
FIGURE 1 ARV DRUGS SALES REVENUE BY GEOGRAPHIC REGIONS, 2012-2018 (\$ BILLIONS)	24
NORTH AMERICAN HIV MARKET	25
REGULATIONS IMPACTING THE GROWTH OF NORTH AMERICAN HIV MARKET	25
MARKET FORECAST	26
EUROPEAN HIV MARKET	26
TABLE 8 EUROPEAN COUNTRIES BY RATES OF HIV DIAGNOSIS (%)	27
TABLE 9 PATTERN OF HIV INFECTION BY EUROPEAN REGIONS, 2012	27
TRENDS IN EUROPEAN HIV MARKET	27
TABLE 10 SALES REVENUE OF ARV DRUGS IN EU5 COUNTRIES, THROUGH 2018 (\$ BILLIONS)	27
TABLE 11 HIV THERAPEUTICS MARKET SHARE BY EU5 COUNTRIES, 2012-2018 (%)	28
FIGURE 2 SALES REVENUE OF ARV DRUGS IN EU5 COUNTRIES (\$ BILLIONS)	28
TABLE 12 HIV PREVALENCE IN EU5 COUNTRIES, 2012	29
TABLE 13 RATE OF LATE DIAGNOSIS BY REGIONS OF THE U.K. (%)	30
MARKET FORECAST	30
THE ASIAN HIV MARKET	31
TABLE 14 HIV PREVALENCE AND INCIDENCE OF NEW INFECTIONS IN ASIAN COUNTRIES, 2012	31
TABLE 15 SALES REVENUE OF ARV DRUGS IN LEADING ASIAN MARKETS, THROUGH 2018 (\$ BILLIONS)	31
TABLE 16 HIV MARKET SHARE BY LEADING ASIAN COUNTRIES, 2012-2018 (%)	31
FIGURE 3 SALES REVENUE OF ARV DRUGS IN LEADING ASIAN MARKETS, 2012-2018 (\$ BILLIONS)	32
TRENDS IN THE ASIAN HIV MARKET	32
MARKET FORECAST	33
HIV MARKET IN ROW	33
HIV MARKET TRENDS IN THE ROW	33
MARKET FORECAST	33
GLOBAL INVESTMENT IN HIV RESEARCH	34
TABLE 17 FORECAST GLOBAL ANNUAL INVESTMENT IN HIV RESEARCH, THROUGH 2018 (\$ BILLIONS)	34
TABLE 18 GLOBAL INVESTMENT SHARE BY AREA OF RESEARCH, 2012-2018 (%)	34
TABLE 19 INVESTMENT BY DONOR TYPE (%)	35
INVESTMENT IN HIV THERAPEUTICS	35
TABLE 20 INVESTMENT IN HIV THERAPEUTICS BY DRUG SUBCATEGORIES IN 2012 (%)	36
INVESTMENT IN HIV VACCINES	36

TOPIC	PAGE NO.
INVESTMENT IN HIV PROPHYLAXIS	36
<i>TABLE 21 INVESTMENT BY MODE OF HIV PROPHYLAXIS (%)</i>	37
INVESTMENT IN HIV DIAGNOSTICS	37
INVESTMENT FOR OTHER RESEARCH ASSOCIATED WITH HIV	37
GENERIC HIV DRUGS MARKET	37
<i>FIGURE 4 GENERIC VS. BRANDED ARV DRUGS GLOBAL SALES REVENUE, 2012-2018 (\$ BILLIONS)</i>	37
<i>FIGURE 5 GENERIC ARV DRUGS GLOBAL SALES REVENUE GROWTH (\$ MILLIONS/%)</i>	38
DRIVERS FOR THE GROWTH OF GENERIC HIV DRUGS MARKET	39
<i>TABLE 22 LEADING ARV DRUGS ON PATENT CLIFF</i>	39
RESTRAINTS TO THE GROWTH OF GENERIC HIV DRUGS MARKET	40
<i>TABLE 23 DRIVERS AND RESTRAINTS OF GENERIC HIV MARKET</i>	40
CHAPTER SUMMARY	41
<i>TABLE 24 DRIVERS AND RESTRAINTS OF GLOBAL HIV MARKET</i>	41
CHAPTER 5 HIV THERAPEUTICS MARKET: LEADING ARV DRUG CATEGORIES	43
THERAPY BY LINE-TREATMENT	43
<i>TABLE 25 RECOMMENDED ARV TREATMENT BY THE WHO</i>	44
FIRST-LINE TREATMENT REGIMEN	44
SECOND-LINE TREATMENT REGIMEN	44
THIRD-LINE/SALVAGE TREATMENT REGIMEN	45
ARV MARKET BY DRUG CATEGORIES	45
<i>TABLE 26 HIV THERAPEUTICS MARKET BY DRUG CATEGORY, THROUGH 2018 (\$ BILLIONS)</i>	46
<i>TABLE 27 HIV THERAPEUTICS MARKET SHARE BY DRUG CATEGORY, 2012-2018 (%)</i>	46
<i>FIGURE 6 HIV THERAPEUTICS MARKET BY DRUG CATEGORY 2012-2018 (%)</i>	46
NRTIS	47
<i>TABLE 28 LIST OF APPROVED NRTIS (AND TABLE UNITS)</i>	47
Mechanism of Action:	48
Resistance to NRTIs	48
Market Status	48
Market Forecast	49
NNRTIS	49
<i>TABLE 29 LIST OF APPROVED NNRTIS</i>	49
Mechanism of Action	50
Drug Resistance and Adverse Effects	50
Market Status	50
Market Forecast	50
PROTEASE INHIBITORS	51
<i>TABLE 30 LIST OF APPROVED PROTEASE INHIBITORS</i>	51
Pharmacokinetic Boosters	52
Market Forecast	52
INTEGRASE STRAND TRANSFER INHIBITORS	52
<i>TABLE 31 LIST OF APPROVED INTEGRASE INHIBITOR DRUGS</i>	52
Market Forecast	53
ENTRY INHIBITORS	53
<i>TABLE 32 LIST OF APPROVED ENTRY INHIBITORS</i>	53
Mechanism of Action	54

TOPIC	PAGE NO.
Market Forecast	54
SINGLE TABLET REGIMEN (STR) FIXED-DOSE COMBINATION (FDC) DRUGS	54
<i>TABLE 33 LIST OF APPROVED STR FDC DRUGS</i>	55
Market Forecast	55
CHAPTER SUMMARY	55
<i>TABLE 34 MARKET DRIVERS AND RESTRAINTS OF ARV DRUGS, BY CLASS</i>	57
CHAPTER 6 HIV THERAPEUTICS MARKET: LEADING DRUGS	59
LEADING EIGHT HIV DRUGS CLAIMED OVER 80% OF THE MARKET SHARE	59
<i>TABLE 35 SALES REVENUE FORECAST OF LEADING HIV DRUGS, THROUGH 2018 (\$ BILLIONS)</i>	59
<i>TABLE 36 HIV MARKET SHARE BY LEADING DRUGS (%)</i>	60
<i>FIGURE 7 HIV MARKET SHARE BY LEADING DRUGS (%)</i>	60
ATRIPLA	61
Generic Atripla for PEPFAR Countries	61
Competitors	61
Market Forecast	61
TRUVADA	62
Truvada as a Prophylactic Drug	62
Market Forecast	62
EPZICOM	62
HLA-B*5701 Testing	63
Clinical Trials	63
Patents and Competition	63
Market Forecast	63
VIREAD	64
Viread Prodrug	64
Market Forecast	64
PREZISTA	64
Clinical Trials	64
Patents	65
Competitors	65
Market Forecast	65
REYATAZ	65
Competitors	65
Market Forecast	66
KALETRA	66
Competitors	66
Market Forecast	66
ISENTRESS	67
Clinical Trials	67
Competitors	67
Market Forecast	68
PROMISING EMERGING THERAPIES	68
STRIBILD	68
Clinical Trials	68
Competitors	69
Market Forecast	69

TOPIC	PAGE NO.
TIVICAY	69
Clinical Trials	70
Competitors	70
Market Forecast	70
COMPLERA	70
Clinical Trials	71
Patent	71
Market Forecast	71
INTELENCE	71
Market Forecast	72
OTHER DRUGS	72
COMBIVIR	72
Competition	72
SUSTIVA	72
NORVIR	73
SELZENTRY	73
Clinical Trials	73
Market Forecast	73
OTHER ARV DRUGS IN THE MARKET	73
CHAPTER SUMMARY	74
<i>FIGURE 8 RANKING (BY MARKET SHARE) OF LEADING ARV DRUGS, 2012-2018</i>	74
<i>TABLE 37 MARKET DRIVERS AND RESTRAINTS OF THE LEADING ARV DRUGS</i>	75
CHAPTER 7 ARV DRUGS PIPELINE ANALYSIS	77
<i>FIGURE 9 NUMBER OF CLINICAL TRIALS BY DEVELOPMENTAL PHASE</i>	77
NRTI DRUGS IN DEVELOPMENT	78
TENOFOVIR ALAFENAMIDE (TAF)	78
Clinical Trials	78
Market Potential	78
NNRTIS IN DEVELOPMENT	79
<i>TABLE 38 ONGOING CLINICAL TRIALS OF NNRTI DRUGS IN DEVELOPMENT</i>	79
MK1439	79
Clinical Trials	79
Market Potential	80
RILPIVIRINE (LA)	80
Clinical Trials	80
Market Potential	80
INTEGRASE INHIBITORS IN DEVELOPMENT	80
S/GSK1265744	81
Clinical Trials	81
Market Potential	82
ENTRY INHIBITORS IN DEVELOPMENT	82
CENICRIVIROC	82
Clinical Trials	82
Market Potential	83
ALBUVIRTIDE	83
Clinical Trials	83

TOPIC	PAGE NO.
Market Potential	83
BMS-663068	83
COMBINATION THERAPIES	83
<i>TABLE 39 ONGOING CLINICAL TRIALS OF STR FDC DRUGS</i>	84
572 TRII	84
Clinical Trials	85
Market Potential	85
OTHER STR FDC DRUGS IN DEVELOPMENT	85
PHARMACOKINETIC BOOSTERS IN DEVELOPMENT	85
EMERGING THERAPIES	86
<i>TABLE 40 ONGOING CLINICAL TRIALS OF EMERGING THERAPIES</i>	86
SB-728-T	86
Clinical Trials	87
Market Potential	87
KP-1461	87
Clinical Trials	87
LEXGENLEUCEL-T (VRX-496)	88
Clinical Trials	88
Market Potential	88
SL9-TCR GENE THERAPY	88
Clinical Trials	89
IMMUNOMODULATORS	89
MONOCLONAL ANTIBODIES AGAINST HIV	89
CHAPTER SUMMARY	90
<i>TABLE 41 OVERVIEW OF ARV DRUGS IN DEVELOPMENT</i>	90
CHAPTER 8 HIV TESTING AND DIAGNOSTICS	93
EARLY DETECTION	93
PATIENT STAGING	93
TREATMENT SWITCHING	93
HIV SCREENING TESTS	94
HIV CONFIRMATORY TESTS	94
HIV MONITORING TESTS	94
TYPES OF HIV TESTS	94
ANTIGEN- AND ANTIBODY-BASED TESTS FOR HIV	94
<i>TABLE 42 HIV RAPID TESTS ADVANTAGES AND DISADVANTAGES BY CLIA* COMPLEXITY AND GENERATION</i>	95
<i>TABLE 43 FDA APPROVED ANTIBODY HIV TESTS</i>	96
<i>TABLE 44 FDA APPROVED ANTIGEN-ANTIBODY COMBO TESTS</i>	97
CD4 TESTING	97
<i>TABLE 45 CD4 TESTS IN THE MARKET</i>	98
VIRAL LOAD TESTING	98
<i>TABLE 46 LIST OF MARKETED VIRAL LOAD TESTS</i>	99
SELECTED RAPID HIV TESTS	99
ALERE DETERMINE HIV-1/2 AG/AB COMBO TEST	99
CHEMBIO'S DPP(R) HIV 1/2 ASSAY	100
CLEARVIEW ® HIV 1/2 STAT-PAK ®	100
REVEAL G3 RAPID HIV-1 ANTIBODY TEST	100

TOPIC	PAGE NO.
PRISM HIV AG/AB COMBO ASSAY	100
SELECTED CD4 TESTS	100
BD FACSCALIBUR™ FLOW CYTOMETER	101
CYTOMICS FC 500™ MCL/MPL SYSTEM	101
CYFLOW COUNTER	101
MILLIPORE-GUAVA AUTO CD4/CD4% SYSTEM	102
APOGEE AUTO40 FLOW CYTOMETER	102
AQUIOS CL	102
POINT OF CARE CD4 TESTING ASSAYS	102
PointCare NOW	102
Pima CD4 Analyser	102
CyFlow™ CD4 miniPOC	103
SELECTED VIRAL LOAD TESTS	103
COBAS AMPLIPREP/COBAS TAQMAN HIV-1 SYSTEM	103
ABBOTT REALTIME HIV-1	103
VERSANT HIV RNA 1.0 (KPCR)	104
ARTUS HIV-1 RS/QS-RGQ KIT	104
NUCLISENS EASYQ HIV-1	104
VERSANT® HIV-1 RNA 3.0 ASSAY	104
NON-NUCLEIC ACID-BASED VIRAL LOAD ASSAYS	104
ExaVir Load Version 3.0	105
HIV DIAGNOSTICS PIPELINE	105
<i>TABLE 47 HIV/AIDS DIAGNOSTICS PIPELINE</i>	105
DAKTARI CD4 COUNTER	106
MBIO CD4 SYSTEM	106
VISITECT CD4	107
ZYOMYX MYT4 TEST	107
ALERE'S NAT SYSTEM	107
LIAT ANALYSER	108
SAMBA	108
EOSCAPE-HIV RAPID RNA ASSAY SYSTEM	109
LYNX HIV P24 ANTIGEN ASSAY	109
PANNAT PLATFORM	109
HIV DIAGNOSTICS MARKET	109
<i>TABLE 48 HIV DIAGNOSTICS MARKET BY TYPES OF TESTS, THROUGH 2018 (\$ BILLIONS)</i>	110
<i>TABLE 49 HIV DIAGNOSTICS MARKET SHARE BY TYPES OF TESTS, 2012-2018 (%)</i>	110
RAPID HIV TESTING MARKET	110
Forecast for Rapid HIV Testing Market	111
CD4 TESTING MARKET	111
<i>TABLE 50 CD4 TESTING MARKET SHARE IN SEVEN SUB-SAHARAN AFRICAN COUNTRIES, 2012 (%)</i>	111
Forecast for CD4 Testing Market	112
<i>TABLE 51 GLOBAL DEMAND FOR CD4 TESTING, 2012-2018 (MILLIONS)</i>	112
VIRAL LOAD TESTING MARKET	112
Forecast for Viral Load Testing Market	112
<i>TABLE 52 GLOBAL DEMAND FOR VIRAL LOAD TESTING, 2012-2018 (MILLIONS)</i>	113
CHAPTER SUMMARY	113

TOPIC	PAGE NO.
<i>TABLE 53 MARKET DRIVERS AND RESTRAINTS FOR HIV TESTING PRODUCTS</i>	114
CHAPTER 9 HIV PROPHYLAXIS	116
HIV PROPHYLAXIS BASED ON EXPOSURE	116
EARLY PROPHYLAXIS	116
PRE-EXPOSURE PROPHYLAXIS	116
CLINICAL STUDIES IN SUPPORT OF HIV PREP	117
Bangkok Tenofovir Study	117
HPTN 052	117
PopART Study	117
LONG ACTING FORMULATIONS OF EXISTING ARV DRUGS	118
<i>TABLE 54 CLINICAL TRIALS TESTING DRUG-BASED PREP, 2014 AND 2015</i>	118
MICROBICIDES AND VAGINAL RINGS	119
Centers for Disease Control and Prevention	119
Failure of the VOICE Trial	120
CAPRISA	120
ASPIRE and "IPM 027"	120
<i>TABLE 55 ONGOING CLINICAL TRIALS OF MICROBICIDES, 2014 AND 2015</i>	121
MALE CIRCUMCISION	122
POST-EXPOSURE PROPHYLAXIS (PEP)	122
PREVENTING TRANSMISSION FROM MOTHER TO CHILD	123
<i>TABLE 56 EVOLUTION OF WHO GUIDELINES WITH REGARDS TO PMTCT, 2006-2013</i>	123
<i>TABLE 57 SELECTED ON-GOING TRIALS ON PMTCT, 2013-2017</i>	124
CHAPTER SUMMARY	127
CHAPTER 10 HIV VACCINES	129
HURDLES FOR DEVELOPING HIV VACCINES	129
PROPHYLACTIC VS. THERAPEUTIC HIV VACCINES	129
TYPES OF HIV VACCINES	130
<i>TABLE 58 TYPE OF HIV VACCINES</i>	130
THE HISTORIC RV144 TRIAL	131
RECENT ADVANCES IN HIV VACCINE RESEARCH	132
GEOVAX'S PROPHYLACTIC AND THERAPEUTIC VACCINE DUAL TECHNOLOGY	132
<i>TABLE 59 ONGOING CLINICAL TRIALS OF PROPHYLACTIC HIV VACCINES</i>	132
<i>TABLE 60 ONGOING CLINICAL TRIALS FOR THERAPEUTIC HIV VACCINES</i>	133
FUTURE HOPES OF A SUCCESSFUL HIV VACCINE	134
CHAPTER 11 QUALITATIVE ANALYSIS	137
PORTER'S 5 ANALYSIS	137
<i>FIGURE 10 GLOBAL HIV THERAPEUTICS MARKET ANALYSIS</i>	137
COMPETITIVE RIVALRY WITHIN INDUSTRY	137
THREAT OF NEW ENTRANTS	138
THREAT OF SUBSTITUTE PRODUCTS	138
Leading Drugs on Patent Cliff	138
Drug Counterfeiting	138
BARGAINING POWER OF SUPPLIERS	139
BARGAINING POWER OF CUSTOMERS	139

TOPIC	PAGE NO.
TRIPS Flexibilities	139
Compulsory Licensing and Parallel Imports	139
Negotiations for Low-Priced Drugs	139
Promoting Free Trade	139
Patents for Public Health	140
CHALLENGES OF THE HIV MARKET	140
ACCESSIBILITY TO ARV THERAPY	140
ADHERENCE TO DRUG REGIMENS	140
<i>TABLE 61 RETENTION TO TREATMENT (%)</i>	141
P4P4P	141
Combination Pills	141
HIGH COST OF TREATMENT	142
First-Line vs. Second-Line Treatment	142
<i>TABLE 62 FIRST-LINE VS. SECOND-LINE TREATMENT MEDIAN PRICE, 2012 (IN \$US PER PERSON PER YEAR)</i>	142
Cost of STR FDC Pills	142
PEDIATRIC FORMULATIONS OF ARV DRUGS	143
LATE DIAGNOSIS OF HIV INFECTION	143
ACCESSIBILITY TO HIV DIAGNOSTICS	144
COMPLEXITY OF VIRAL LOAD TESTING	144
ADHERENCE CHALLENGES IN PRE-EXPOSURE PROPHYLAXIS	145
REGULATORY AND POLITICAL CHALLENGES	145
HIGH VARIABILITY OF HIV	145
OPPORTUNITIES FOR REVENUE GENERATION	146
DRUGS FOR TREATMENT-EXPERIENCED PATIENTS	146
DRUGS WITH LONG HALF-LIFE	146
EARLY INFANT DIAGNOSIS	146
PREVENTING TREATMENT SWITCHES	147
DECENTRALIZATION OF HIV TESTING	147
DEMAND FOR SIMPLE, IMPROVED LOW-COST TESTING DEVICES	147
DRIVERS OF THE HIV MARKET	148
LONGEVITY OF HIV-INFECTED PATIENTS	148
INCREASE IN AWARENESS PROGRAMS	148
INCREASE IN ACCESS TO THERAPEUTICS AND DIAGNOSTICS	148
FOURTH-GENERATION RAPID HIV TESTING	148
POINT-OF-CARE DIAGNOSTICS	149
IMPLICATIONS OF RECENT REGULATORY GUIDELINES	149
RESTRAINTS TO THE GROWTH OF HIV MARKET	150
SOCIAL STIGMA ASSOCIATED WITH HIV TESTING	150
HIGH PRICE FOR NEW DRUGS EVENTUALLY REDUCING THEIR UPTAKE	150
PMTCT WILL REDUCE PEDIATRIC HIV MARKET	150
ECONOMIC SLOWDOWN	150
HARMONIZATION	151
PUBLIC-PRIVATE PARTNERSHIPS	151
CORPORATE RESPONSIBILITY	152
HARMONY AMONG REGULATORY AGENCIES	152
CHAPTER SUMMARY	153
<i>TABLE 63 CHALLENGES AND OPPORTUNITIES IN THE GLOBAL HIV MARKET</i>	154

TOPIC	PAGE NO.
<i>TABLE 64 MAJOR DRIVERS AND RESTRAINTS IN THE GLOBAL HIV MARKET</i>	155
CHAPTER 12 COMPANY PROFILES	157
HIV THERAPEUTICS-LEADING COMPANIES	157
<i>TABLE 65 HIV THERAPEUTICS MARKET SHARE BY LEADING COMPANIES, 2012-2018 (\$ BILLIONS)</i>	157
<i>FIGURE 11 HIV THERAPEUTICS MARKET SHARE BY LEADING COMPANIES (%)</i>	157
ABBVIE INC	158
BRISTOL-MYERS SQUIBB	159
Bristol-Myers Squibb Pharmaceuticals Limited (Uxbridge)	159
GILEAD SCIENCES	159
JANSSEN THERAPEUTICS	160
MERCK & CO. INC	161
VIIV HEALTHCARE	162
U.S. headquarters	162
HIV DIAGNOSTICS: LEADING COMPANIES	163
ABBOTT LABORATORIES	163
ALERE	163
BD BIOSCIENCES	164
BD	164
ROCHE	165
SIEMENS HEALTHCARE DIAGNOSTICS	165
SELECTED EMERGING AND GENERIC COMPANIES IN THE GLOBAL HIV MARKET	166
ASPEN GROUP	166
KORONIS PHARMACEUTICALS (VDA PHARMA)	167
MYLAN	167
SANGAMO BIOSCIENCES	167
CHAPTER 13 APPENDIX A: GLOSSARY	170
<i>TABLE 66 GLOSSARY</i>	170
CHAPTER 14 APPENDIX B: DRUG ACRONYMS	176
CHAPTER 15 APPENDIX C: ABBREVIATIONS	178
<i>TABLE 67 ABBREVIATIONS</i>	178

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL HIV MARKET, THROUGH 2018 (\$ BILLIONS)	11
TABLE 1 TOP 10 LEADING CAUSES OF DEATHS IN THE WORLD, 2011 (MILLIONS)	13
TABLE 2 BURDEN OF HIV BY GEOGRAPHICAL REGIONS	14
TABLE 3 MILESTONES IN THE HISTORY OF HIV	15
TABLE 4 LIFE CYCLE OF HIV-THERAPEUTICS TARGET POINTS	17
TABLE 5 FORECASTED NUMBER OF PEOPLE RECEIVING ARV THERAPY, 2012-2018 (MILLIONS)	22
TABLE 6 ARV DRUGS SALES REVENUE BY GEOGRAPHIC REGIONS, THROUGH 2018 (\$ BILLIONS)	23
TABLE 7 ARV DRUGS MARKET SHARE BY GEOGRAPHIC REGIONS, 2012-2018 (%)	23
TABLE 8 EUROPEAN COUNTRIES BY RATES OF HIV DIAGNOSIS (%)	26
TABLE 9 PATTERN OF HIV INFECTION BY EUROPEAN REGIONS, 2012	26
TABLE 10 SALES REVENUE OF ARV DRUGS IN EU5 COUNTRIES, THROUGH 2018 (\$ BILLIONS)	26
TABLE 11 HIV THERAPEUTICS MARKET SHARE BY EU5 COUNTRIES, 2012-2018 (%)	27
TABLE 12 HIV PREVALENCE IN EU5 COUNTRIES, 2012	28
TABLE 13 RATE OF LATE DIAGNOSIS BY REGIONS OF THE U.K. (%)	29
TABLE 14 HIV PREVALENCE AND INCIDENCE OF NEW INFECTIONS IN ASIAN COUNTRIES, 2012	30
TABLE 15 SALES REVENUE OF ARV DRUGS IN LEADING ASIAN MARKETS, THROUGH 2018 (\$ BILLIONS)	30
TABLE 16 HIV MARKET SHARE BY LEADING ASIAN COUNTRIES, 2012-2018 (%)	30
TABLE 17 FORECAST GLOBAL ANNUAL INVESTMENT IN HIV RESEARCH, THROUGH 2018 (\$ BILLIONS)	33
TABLE 18 GLOBAL INVESTMENT SHARE BY AREA OF RESEARCH, 2012-2018 (%)	33
TABLE 19 INVESTMENT BY DONOR TYPE (%)	34
TABLE 20 INVESTMENT IN HIV THERAPEUTICS BY DRUG SUBCATEGORIES IN 2012 (%)	35
TABLE 21 INVESTMENT BY MODE OF HIV PROPHYLAXIS (%)	36
TABLE 22 LEADING ARV DRUGS ON PATENT CLIFF	38
TABLE 23 DRIVERS AND RESTRAINTS OF GENERIC HIV MARKET	39
TABLE 24 DRIVERS AND RESTRAINTS OF GLOBAL HIV MARKET	40
TABLE 25 RECOMMENDED ARV TREATMENT BY THE WHO	43
TABLE 26 HIV THERAPEUTICS MARKET BY DRUG CATEGORY, THROUGH 2018 (\$ BILLIONS)	45
TABLE 27 HIV THERAPEUTICS MARKET SHARE BY DRUG CATEGORY, 2012-2018 (%)	45
TABLE 28 LIST OF APPROVED NRTIS (AND TABLE UNITS)	46
TABLE 29 LIST OF APPROVED NNRTIS	48
TABLE 30 LIST OF APPROVED PROTEASE INHIBITORS	50
TABLE 31 LIST OF APPROVED INTEGRASE INHIBITOR DRUGS	51
TABLE 32 LIST OF APPROVED ENTRY INHIBITORS	52
TABLE 33 LIST OF APPROVED STR FDC DRUGS	54
TABLE 34 MARKET DRIVERS AND RESTRAINTS OF ARV DRUGS, BY CLASS	56
TABLE 35 SALES REVENUE FORECAST OF LEADING HIV DRUGS, THROUGH 2018 (\$ BILLIONS)	58
TABLE 36 HIV MARKET SHARE BY LEADING DRUGS (%)	59
TABLE 37 MARKET DRIVERS AND RESTRAINTS OF THE LEADING ARV DRUGS	74
TABLE 38 ONGOING CLINICAL TRIALS OF NNRTI DRUGS IN DEVELOPMENT	78
TABLE 39 ONGOING CLINICAL TRIALS OF STR FDC DRUGS	83

TABLE HEADING	PAGE NO.
TABLE 40 ONGOING CLINICAL TRIALS OF EMERGING THERAPIES	85
TABLE 41 OVERVIEW OF ARV DRUGS IN DEVELOPMENT	89
TABLE 42 HIV RAPID TESTS ADVANTAGES AND DISADVANTAGES BY CLIA* COMPLEXITY AND GENERATION	94
TABLE 43 FDA APPROVED ANTIBODY HIV TESTS	95
TABLE 44 FDA APPROVED ANTIGEN-ANTIBODY COMBO TESTS	96
TABLE 45 CD4 TESTS IN THE MARKET	97
TABLE 46 LIST OF MARKETED VIRAL LOAD TESTS	98
TABLE 47 HIV/AIDS DIAGNOSTICS PIPELINE	104
TABLE 48 HIV DIAGNOSTICS MARKET BY TYPES OF TESTS, THROUGH 2018 (\$ BILLIONS)	109
TABLE 49 HIV DIAGNOSTICS MARKET SHARE BY TYPES OF TESTS, 2012-2018 (%)	109
TABLE 50 CD4 TESTING MARKET SHARE IN SEVEN SUB-SAHARAN AFRICAN COUNTRIES, 2012 (%)	110
TABLE 51 GLOBAL DEMAND FOR CD4 TESTING, 2012-2018 (MILLIONS)	111
TABLE 52 GLOBAL DEMAND FOR VIRAL LOAD TESTING, 2012-2018 (MILLIONS)	112
TABLE 53 MARKET DRIVERS AND RESTRAINTS FOR HIV TESTING PRODUCTS	113
TABLE 54 CLINICAL TRIALS TESTING DRUG-BASED PREP, 2014 AND 2015	117
TABLE 55 ONGOING CLINICAL TRIALS OF MICROBICIDES, 2014 AND 2015	120
TABLE 56 EVOLUTION OF WHO GUIDELINES WITH REGARDS TO PMTCT, 2006-2013	122
TABLE 57 SELECTED ON-GOING TRIALS ON PMTCT, 2013-2017	123
TABLE 58 TYPE OF HIV VACCINES	129
TABLE 59 ONGOING CLINICAL TRIALS OF PROPHYLACTIC HIV VACCINES	131
TABLE 60 ONGOING CLINICAL TRIALS FOR THERAPEUTIC HIV VACCINES	132
TABLE 61 RETENTION TO TREATMENT (%)	140
TABLE 62 FIRST-LINE VS. SECOND-LINE TREATMENT MEDIAN PRICE, 2012 (IN \$US PER PERSON PER YEAR)	141
TABLE 63 CHALLENGES AND OPPORTUNITIES IN THE GLOBAL HIV MARKET	153
TABLE 64 MAJOR DRIVERS AND RESTRAINTS IN THE GLOBAL HIV MARKET	154
TABLE 65 HIV THERAPEUTICS MARKET SHARE BY LEADING COMPANIES, 2012-2018 (\$ BILLIONS)	156
TABLE 66 GLOSSARY	169
TABLE 67 ABBREVIATIONS	177

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL HIV MARKET, 2012-2018 (\$ BILLIONS)	11
FIGURE 1 ARV DRUGS SALES REVENUE BY GEOGRAPHIC REGIONS, 2012-2018 (\$ BILLIONS)	23
FIGURE 2 SALES REVENUE OF ARV DRUGS IN EU5 COUNTRIES (\$ BILLIONS)	27
FIGURE 3 SALES REVENUE OF ARV DRUGS IN LEADING ASIAN MARKETS, 2012-2018 (\$ BILLIONS)	31
FIGURE 4 GENERIC VS. BRANDED ARV DRUGS GLOBAL SALES REVENUE, 2012-2018 (\$ BILLIONS)	36
FIGURE 5 GENERIC ARV DRUGS GLOBAL SALES REVENUE GROWTH (\$ MILLIONS/%)	37
FIGURE 6 HIV THERAPEUTICS MARKET BY DRUG CATEGORY 2012-2018 (%)	45
FIGURE 7 HIV MARKET SHARE BY LEADING DRUGS (%)	59
FIGURE 8 RANKING (BY MARKET SHARE) OF LEADING ARV DRUGS, 2012-2018	73
FIGURE 9 NUMBER OF CLINICAL TRIALS BY DEVELOPMENTAL PHASE	76
FIGURE 10 GLOBAL HIV THERAPEUTICS MARKET ANALYSIS	136
FIGURE 11 HIV THERAPEUTICS MARKET SHARE BY LEADING COMPANIES (%)	156